Viruses, Vol. 12, Pages 1041: Identification of Inhibitors of ZIKV Replication
In this study, we further evaluated the broad-spectrum antiviral activity of the ten identified compounds by testing their activity against ZIKV. Among the ten compounds, Azaribine (SI-MTT = 146.29), AVN-944 (SI-MTT = 278.16), and Brequinar (SI-MTT = 157.42) showed potent anti-ZIKV activity in post-treatment therapeutic conditions. We also observed potent anti-ZIKV activity for Mycophenolate mofetil (SI-MTT = 20.51), Mycophenolic acid (SI-MTT = 36.33), and AVN-944 (SI-MTT = 24.51) in pre-treatment prophylactic conditions and potent co-treatment inhibitory activity for Obatoclax (SI-MTT = 60.58), Azaribine (SI-MTT = 91.51), and Mycophenolate mofetil (SI-MTT = 73.26) in co-treatment conditions. Importantly, the inhibitory effect of these compounds was strain independent, as they similarly inhibited ZIKV strains from both African and Asian/American lineages. Our results support the broad-spectrum antiviral activity of these ten compounds and suggest their use for the development of antiviral treatment options of ZIKV infection.
Source: Viruses - Category: Virology Authors: Desarey Morales Vasquez Jun-Gyu Park Gin és Ávila-Pérez Aitor Nogales Juan Carlos de la Torre Fernando Almazan Luis Martinez-Sobrido Tags: Article Source Type: research
More News: African Health | Databases & Libraries | Food and Drug Administration (FDA) | Guillain-Barr Syndrome | Influenza | Influenza Vaccine | Outbreaks | Study | Uganda Health | USA Health | Vaccines | Virology | Zika Virus